Liraglutide Liraglutide, trade name Victoza, was developed by Novo Nordisk
After 10 years of treatment, the incidence of MALE was significantly lower in the GLP-1RAs group than in the non-GLP-1RAs group (Monfeuga et al., 2024)
The inflammation was so bad that it often hurt to pick things up and use his hands
Patient pattern: Cant stand the thought of hot chicken but cold sliced turkey breast goes down fine
Suppresses appetite (central action): Reduces hunger signals in the brain, leading to decreased food intake and weight loss 1,2
GLP-1 receptors are found in the brain regions that control hunger, and throughout the stomach, intestines, and pancreas allowing semaglutide to impact appetite, digestion, and blood-sugar regulation at the same time